TCRT Stock Explodes As Velaris Deal Fuels 2029 Runway

Alaunos Therapeutics Inc. surged as stocks have been trading up by 29.7 percent on promising cancer immunotherapy pipeline momentum.

Live Update At 07:47:37 EDT: On Wednesday, October 14, 2026 Alaunos Therapeutics Inc. stock [NASDAQ: TCRT] is trending up by 29.7%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TCRT just flipped from sleepy micro-cap to front-page momentum name. The daily chart tells the story. On 2026/10/13, Alaunos Therapeutics opened at $1.73 and ripped to a $4.32 high before closing at $3.03. That’s a massive gap from the prior close of $1.05, and many times the price level where TCRT had churned between roughly $0.74 and $1.27 in the preceding weeks.

Under the hood, Alaunos Therapeutics is still an early-stage biotech. Revenue is tiny at about $5,000, and the company is deeply unprofitable, with pretax margins in steep negative territory and return on equity also heavily negative. Cash was only $124,000 as of 2026/06/30, and working capital sat at about -$198,000, with a current ratio of 0.8. That balance sheet looked fragile before this week.

The new twist is the $350M private placement tied to the Velaris Therapeutics acquisition. That kind of capital completely changes the runway picture for TCRT, which reported operating cash flow of around -$300,000 last quarter. For traders, the numbers scream high risk, high reward: weak legacy fundamentals, but a suddenly fortified cash position and a chart now in full breakout mode.

Why Traders Are Watching TCRT’s Biotech Pivot

TCRT was grinding sideways for weeks. Then Alaunos Therapeutics dropped a double catalyst that every momentum trader dreams about: a transformative deal and big-money funding behind it.

The company completed its acquisition of Velaris Therapeutics, bringing in a new pipeline built around ActRII‑Fc ligand traps and biologics for pulmonary arterial hypertension and related cardiopulmonary diseases. That is not just another early science story. It shifts Alaunos Therapeutics from a tiny platform name into a cardiopulmonary player with multiple shots on goal. The lead asset, VLR199 for pulmonary arterial hypertension, becomes the near-term focus.

Crucially, TCRT didn’t just buy assets; it bought time. The roughly $350M private placement, structured as Series C non‑voting convertible preferred stock, is expected to fund operations into 2029 and push several candidates through proof‑of‑concept and initial regulatory filings. For a micro-cap biotech, that’s a lifetime.

Traders saw that and piled in. Reports show Alaunos Therapeutics shares jumping about 126% after the deal and financing headlines, then surging as much as ~225% on extremely heavy volume as the Series C news circulated. That kind of move tells you this is now a momentum ticker with a real fundamental story behind it.

But TCRT is still a biotech. The preferred stock is convertible, which means dilution risk down the road. The violent squeeze off sub‑$1 levels into the $3–$4 zone creates both opportunity and trap potential. Traders need to respect the volatility, map key support/resistance levels on the daily and intraday charts, and understand that future data on VLR199 and the rest of the Velaris pipeline will drive the next big legs.

Conclusion

Alaunos Therapeutics just rewrote its playbook. Before the Velaris Therapeutics acquisition, TCRT was a cash‑strapped, loss‑making biotech with limited runway and minimal revenue. Now it controls a fresh cardiopulmonary pipeline, including VLR199 for pulmonary arterial hypertension, and has roughly $350M in new capital earmarked to keep the lights on into 2029 and fund proof‑of‑concept work.

From a trading angle, that combination of new story and extended runway explains the explosive price action. TCRT spiking more than 100%–200% on heavy volume is exactly what momentum and gap‑and‑go traders scan for every morning. But the same traits that make Alaunos Therapeutics attractive also make it dangerous: sharp dilution over time, binary trial outcomes, and wild intraday swings.

For active traders, the job now is to treat TCRT as a trading vehicle, not a long-term promise. Study the daily breakout, the intraday levels around $3 and $4, and watch how Alaunos Therapeutics communicates progress on the Velaris pipeline. As millionaire penny stock trader and teacher Tim Sykes, says, “Consistency is key in trading; don’t let emotions dictate your trades.” As Tim Sykes likes to say, “The market rewards preparation, not hope. Learn the pattern, respect the risks, and always be ready to cut losses fast.”

This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks